About This Show
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter. .
Most Recent Episode
Advances in the Treatment of Glioblastoma Multiforme: Is There a Role for Immune Checkpoint Inhibitors?
Host: Brian P. McDonough, MD, FAAFP
Guest: Michael Lim, MD
Despite significant progress in the treatment for glioblastoma multiforme, or GBM, patient outcomes have failed to see a drastic improvement. Recently, immune checkpoint inhibitors have shown promise in treating patients with GBM in cases where conventional treatment options have failed. The rapid progression of GBM necessitates timely and well-informed decisions made on the part of the clinician. This activity will provide the participant with up-to-date evidence regarding the immune system of patients with GBM as well as ongoing and recent clinical data regarding immune checkpoint inhibitors as treatment options. Selected References Andtbacka RH et al. J Clin Oncol. 2015;33:2780-2788. Robert C et al. Lancet. 2014;384:1109-1117. Fecci PE et al. Clin Cancer Res. 2007;13:2158-2167. Garber ST et al. Neuro-Oncology. 2016;18:1357-1366. Hodi FS et al. N Engl J Med. 2010;363:711-723. Jiang et al. Nat Med. 2016;22:851-860. Kantoff. N Engl J Med. 2010;363:411. Kim et al. Clin Cancer Res. 2017;23:124-136. Pardoll DM. Nat Rev Cancer. 2012;12:252-264. Weber J. Semin Oncol. 2010;37:430-439. Zaretsky JM et al. N Engl J Med. 2016;375:819-829. Zeng J et al. Int J Radiat Oncol Biol Phys. 2013;86:343-349.